Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?
Not available.
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-09-01
|
| Series: | Oncology Reviews |
| Subjects: | |
| Online Access: | https://www.oncologyreviews.org/site/article/view/564 |
| _version_ | 1797964736281706496 |
|---|---|
| author | Francesca Negri Camillo Porta |
| author_facet | Francesca Negri Camillo Porta |
| author_sort | Francesca Negri |
| collection | DOAJ |
| description | Not available. |
| first_indexed | 2024-04-11T01:48:37Z |
| format | Article |
| id | doaj.art-3ff2ae292222494d80b9809c76af8fe4 |
| institution | Directory Open Access Journal |
| issn | 1970-5557 1970-5565 |
| language | English |
| last_indexed | 2024-04-11T01:48:37Z |
| publishDate | 2021-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Oncology Reviews |
| spelling | doaj.art-3ff2ae292222494d80b9809c76af8fe42023-01-03T07:01:20ZengFrontiers Media S.A.Oncology Reviews1970-55571970-55652021-09-0115210.4081/oncol.2021.564Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC?Francesca Negri0Camillo Porta1Medical Oncology Unit, University Hospital of Parma, ParmaDepartment of Biomedical Sciences & Human Oncology, University of Bari ‘Aldo Moro’, and Division of Medical Oncology, Azienda Ospedaliero-Universitaria Consorziale Policlinico, BariNot available.https://www.oncologyreviews.org/site/article/view/564Donafenibsorafenibhepatocellular carcinomaChinese patientspatients’ selection. |
| spellingShingle | Francesca Negri Camillo Porta Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? Oncology Reviews Donafenib sorafenib hepatocellular carcinoma Chinese patients patients’ selection. |
| title | Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? |
| title_full | Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? |
| title_fullStr | Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? |
| title_full_unstemmed | Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? |
| title_short | Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? |
| title_sort | donafenib in chinese patients with advanced hepatocellular carcinoma hcc really a new standard of care or should we change paradigm for drug development in hcc |
| topic | Donafenib sorafenib hepatocellular carcinoma Chinese patients patients’ selection. |
| url | https://www.oncologyreviews.org/site/article/view/564 |
| work_keys_str_mv | AT francescanegri donafenibinchinesepatientswithadvancedhepatocellularcarcinomahccreallyanewstandardofcareorshouldwechangeparadigmfordrugdevelopmentinhcc AT camilloporta donafenibinchinesepatientswithadvancedhepatocellularcarcinomahccreallyanewstandardofcareorshouldwechangeparadigmfordrugdevelopmentinhcc |